Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers from Medical University of Vienna detail new studies and findings in the area of breast cancer
May 8th, 2008
According to a study from Vienna, Austria, "The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifenbased therapy. We assessed expression of cyclin D1 in surgical specimens of breast carcinoma by means of immunohistochemistry." "Patients had been enrolled in either Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 05 or ABCSG Trial 06 and received tamoxifen as part of their adjuvant treatment. Overall survival and relapse-free survival were analyzed with Cox models adjusted for clinical and pathologic factors. Cyclin D1 was expressed in 140...
Source: Women's Health Weekly (2008-05-08)
|
